Imugene Ltd - Asset Resilience Ratio
Imugene Ltd (IMU) has an Asset Resilience Ratio of 23.07% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Imugene Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1995–2025)
This chart shows how Imugene Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Imugene Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Imugene Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Imugene Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$14.14 Million | 20.89% |
| Short-term Investments | AU$1.47 Million | 2.18% |
| Total Liquid Assets | AU$15.61 Million | 23.07% |
Asset Resilience Insights
- Good Liquidity Position: Imugene Ltd maintains a healthy 23.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Imugene Ltd Industry Peers by Asset Resilience Ratio
Compare Imugene Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Imugene Ltd (1995–2025)
The table below shows the annual Asset Resilience Ratio data for Imugene Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 2.49% | AU$2.08 Million ≈ $1.47 Million |
AU$83.59 Million ≈ $59.14 Million |
-31.20pp |
| 2024-06-30 | 33.69% | AU$51.01 Million ≈ $36.09 Million |
AU$151.40 Million ≈ $107.12 Million |
+8.55pp |
| 2023-06-30 | 25.14% | AU$49.54 Million ≈ $35.05 Million |
AU$197.06 Million ≈ $139.43 Million |
+5.49pp |
| 2022-06-30 | 19.65% | AU$29.00 Million ≈ $20.52 Million |
AU$147.61 Million ≈ $104.44 Million |
-9.60pp |
| 2021-06-30 | 29.25% | AU$21.00 Million ≈ $14.86 Million |
AU$71.81 Million ≈ $50.81 Million |
-9.10pp |
| 2020-06-30 | 38.34% | AU$25.00 Million ≈ $17.69 Million |
AU$65.20 Million ≈ $46.14 Million |
-17.52pp |
| 2019-06-30 | 55.87% | AU$17.20 Million ≈ $12.17 Million |
AU$30.78 Million ≈ $21.78 Million |
+9.62pp |
| 2018-06-30 | 46.25% | AU$7.82 Million ≈ $5.53 Million |
AU$16.91 Million ≈ $11.97 Million |
+8.27pp |
| 2017-06-30 | 37.97% | AU$4.81 Million ≈ $3.41 Million |
AU$12.68 Million ≈ $8.97 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$9.54 Million ≈ $6.75 Million |
-- |
| 1996-06-30 | 4.18% | AU$387.00K ≈ $273.83K |
AU$9.25 Million ≈ $6.54 Million |
+0.33pp |
| 1995-06-30 | 3.86% | AU$460.00K ≈ $325.48K |
AU$11.93 Million ≈ $8.44 Million |
-- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more